{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:40:26Z","timestamp":1792813226455,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.clml.2012.01.010","type":"journal-article","created":{"date-parts":[[2012,4,25]],"date-time":"2012-04-25T23:46:23Z","timestamp":1335397583000},"page":"238-243","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Pralatrexate Is an Effective Treatment for Relapsed or Refractory Transformed Mycosis Fungoides: A Subgroup Efficacy Analysis From the PROPEL Study"],"prefix":"10.1016","volume":"12","author":[{"given":"Francine","family":"Foss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Horwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Coiffier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Popplewell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Pro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren C.","family":"Pinter-Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Shustov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard R.","family":"Furman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Haioun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Koutsoukos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen A.","family":"O'Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 3","key":"10.1016\/j.clml.2012.01.010_bib1","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1080\/10428190310001623757","article-title":"Overview of cutaneous T-cell lymphoma: prognostic factors and novel therapeutic approaches","volume":"44","author":"Foss","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2012.01.010_bib2","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1365-2133.2007.08008.x","article-title":"Transformed mycosis fungoides: clinicopathological features and outcome","volume":"157","author":"Barberio","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clml.2012.01.010_bib3","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000121002","article-title":"Treatment of transformed mycosis fungoides with intermittent low-dose gemcitabine","volume":"73","author":"Awar","year":"2007","journal-title":"Oncology"},{"key":"10.1016\/j.clml.2012.01.010_bib4","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1182\/blood-2008-05-154609","article-title":"Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation","volume":"112","author":"Arulogun","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.01.010_bib5","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1182\/blood.V92.4.1150","article-title":"Transformation of mycosis fungoides\/Sezary syndrome: clinical characteristics and prognosis","volume":"92","author":"Diamandidou","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.01.010_bib6","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1182\/blood-2009-07-202895","article-title":"How I treat mycosis fungoides and Sezary syndrome","volume":"114","author":"Prince","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.01.010_bib7","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1001\/archderm.144.6.727","article-title":"Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or S\u00e9zary syndrome","volume":"144","author":"Quereux","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clml.2012.01.010_bib8","doi-asserted-by":"crossref","first-page":"6217","DOI":"10.1158\/1078-0432.CCR-09-0162","article-title":"A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders","volume":"15","author":"Duvic","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2012.01.010_bib9","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1200\/JCO.2009.25.8301","article-title":"Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and S\u00e9zary syndrome","volume":"28","author":"Duvic","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.01.010_bib10","first-page":"2212","article-title":"Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases","volume":"95","author":"Vergier","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.01.010_bib11","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0190-9622(99)70079-4","article-title":"Prognostic factor analysis in mycosis fungoides\/S\u00e9zary syndrome","volume":"40","author":"Diamandidou","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clml.2012.01.010_bib12","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O'Connor","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.01.010_bib13","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s002800050823","article-title":"A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice","volume":"42","author":"Sirotnak","year":"1998","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clml.2012.01.010_bib14","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/1042819031000077124","article-title":"Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression","volume":"44","author":"Wang","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2012.01.010_bib15","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1158\/1078-0432.CCR-10-0671","article-title":"Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies","volume":"16","author":"Marchi","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2012.01.010_bib16","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.01.010_bib17","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1158\/1078-0432.CCR-06-1754","article-title":"A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors","volume":"13","author":"Azzoli","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2012.01.010_bib18","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2001.19.2.376","article-title":"Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma","volume":"19","author":"Olsen","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.01.010_bib19","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.01.010_bib20","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/archderm.138.1.42","article-title":"Quantifying skin disease burden in mycosis fungoides-type cutaneous T-cell lymphomas: the severity-weighted assessment tool (SWAT)","volume":"138","author":"Stevens","year":"2002","journal-title":"Arch Dermatol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265012000468?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265012000468?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:22:13Z","timestamp":1761870133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265012000468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S2152265012000468"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2012.01.010","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pralatrexate Is an Effective Treatment for Relapsed or Refractory Transformed Mycosis Fungoides: A Subgroup Efficacy Analysis From the PROPEL Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2012.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}